A5101460069- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Pleural and Pulmonary Diseases
- Occupational and environmental lung diseases
- Obstructive Sleep Apnea Research
GlaxoSmithKline (Spain)
2013-2023
The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits generalizability results. Our study evaluated effectiveness and safety patients with Spain. primary endpoint was change rate clinically significant exacerbations 12 months after starting compared to baseline prior treatment. Patients were stratified blood eosinophil counts. We conducted a multicentric observational cohort treated...
Population distribution of reduced diffusing capacity the lungs for carbon monoxide (DLCO) in smokers and main consequences are not properly recognised. The objectives this study were to describe prevalence DLCO a population-based sample current former smoker subjects without airflow limitation its morphological, functional clinical implications.
To compare the score indicative of asthma control obtained using Asthma Control Test (ACT(®)) questionnaire administered by primary health care physicians, habitual users questionnaire, and those were not.A multicentre, prospective, epidemiological study.Primary centres in Spain.Two study populations defined: «ACT(®) users» «non-ACT(®) users», according to use ACT(®) their respective physicians.The patients completed during a baseline visit, another follow-up visit at 8 weeks. The outcome...
<b>Introduction:</b> On-treatment clinical remission (CR) is an aspirational goal in asthma management, with groups trying to agree on a definition. In post hoc analysis of the real-world REDES study, after 52 weeks mepolizumab, 37% patients severe (SA) achieved 3-component definition CR (oral corticosteroid-free, exacerbation-free, Asthma Control Test score ≥20). <b>Aim:</b> Assess impact different lung function outcomes (as fourth component) outcome. <b>Methods:</b> This assessed...